Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Nov 3:16:1678151.
doi: 10.3389/fneur.2025.1678151. eCollection 2025.

Ocular myasthenia gravis management

Mark J Kupersmith  1 , Gil I Wolfe  2 , Henry Kaminski  3
Affiliations
Review

Ocular myasthenia gravis management

Mark J Kupersmith et al. Front Neurol. .

Abstract

Ocular myasthenia gravis (OMG) has no agreed-upon diagnostic and management criteria, leading to misdiagnoses and often misguided treatments. The purpose of this minireview is to provide guidance to clinicians who encounter possible OMG patients. We cite relevant literature and the recommendations for diagnosis and therapy based on the authors' extensive experience in OMG. This report provides sound recommendations based on the authors' successes and failures, coupled with relevant literature in the myasthenia gravis field.

Keywords: OMG; OMG mimics; myasthenia gravis diagnosis; myasthenia gravis treatment; ocular myasthenia gravis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Suzuki S, Murai H, Imai T, Nagane Y, Masuda M, Tsuda E, et al. Quality of life in purely ocular myasthenia in Japan. BMC Neurol. (2014) 14:142. doi: 10.1186/1471-2377-14-142, PMID: - DOI - PMC - PubMed
    1. Verma R, Wolfe GI, Kupersmith MJ. Ocular myasthenia gravis–how effective is low dose prednisone long term? J Neurol Sci. (2021) 420:117274. doi: 10.1016/j.jns.2020.117274, PMID: - DOI - PubMed
    1. Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. (1997) 62:156–62. doi: 10.1136/jnnp.62.2.156, PMID: - DOI - PMC - PubMed
    1. Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology. (1984) 34:170–4. doi: 10.1212/wnl.34.2.170, PMID: - DOI - PubMed
    1. Bruce BB, Kupersmith MJ. Safety of prednisone for ocular myasthenia gravis. J Neuroophthalmol. (2012) 32:212–5. doi: 10.1097/WNO.0b013e3182536558, PMID: - DOI - PMC - PubMed

LinkOut - more resources